VaccinesVaccines and autoimmune diseases in adults—what do doctors outside the mainstream say?
- Stowarzyszenie STOP NOP — Lekarze ostrzegają! Szczepionka HPV – Ogólnopolskie Stowarzyszenie Wiedzy o Szczepieniach "STOP NOP"
- Stowarzyszenie STOP NOP — Szczepienia – poznaj ich ryzyko i skuteczność – Ogólnopolskie Stowarzyszenie Wiedzy o Szczepieniach "STOP NOP"
- Stowarzyszenie STOP NOP — Dr n.med. Dorota Sienkiewicz „Bezpieczne szczepienia” – alternatywny kalendarz szczepień – Ogólnopolskie Stowarzyszenie Wiedzy o Szczepieniach "STOP NOP"
- Hubert Czerniak — Wyleczyć nieuleczalne – autyzm
- Prof. Sucharit Bhakdi — mRNA Vaccine Toxicity — M. Palmer i S. Bhakdi i in. (2023)
- Prof. Sucharit Bhakdi — mRNA vaccines against COVID-19 and their effects on the central nervous system
- Autoimmune diseases after hepatitis B immunization in adults: Literature review and meta-analysis, with reference to 'autoimmune/autoinflammatory syndrome induced by adjuvants' (ASIA). · Vaccine 2018
- Vaccines and the risk of Guillain-Barré syndrome. · Eur J Epidemiol 2020
- Influenza and herpes zoster vaccine effectiveness in autoimmune or immune-mediated diseases. · J Infect Public Health 2026
- COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis. · Rheumatology (Oxford) 2023
- IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19 Infections in Immunocompromised Patients. · Clin Infect Dis 2026
- IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19, Influenza, and RSV Infections in Immunocompromised Patients. · Clin Infect Dis 2026
- Orthomolecular Medicine News Service — VACCINATIONS: To Be or Not to Be
- Orthomolecular Medicine News Service — VACCINE ADJUVANTS AND EXCIPIENTS: Know what else comes through the needle?
- Orthomolecular Medicine News Service — Flu Vaccine: No Good Evidence
Prof. Sucharit Bhakdi cites a summary of 87 cases of hepatitis after COVID-19 vaccination, including 34 in which no autoantibodies were detected.
- In the case described, he said a possible explanation was an immune attack against the spike protein, rather than autoimmunity.
- Bhakdi also describes cases of encephalitis diagnosed as autoimmune; he points out that their cause often cannot be determined without examining tissue.
- The STOP NOP Association cites findings linking HPV vaccination to hypothyroidism, autoimmune thyroiditis, and serious autoimmune adverse events.
What the authors write
The STOP NOP Association cites findings indicating a possible link between HPV vaccination and hypothyroidism and autoimmune thyroiditis.
The STOP NOP Association cites a study linking HPV4 vaccination to a serious autoimmune adverse event.
Plaintiffs in cases involving the Gardasil vaccine alleged, among other things, that it caused autoimmune disorders.
The STOP NOP Association says that the committee did not determine whether the childhood vaccination schedule is linked to autoimmune diseases.
The STOP NOP Association links the deterioration in children's health, which coincided with the wider use of vaccines, to the occurrence of autoimmune diseases.
Hubert Czerniak claims that keeping a child in TH2 mode can lead to autoimmune diseases, and therefore advocates starting vaccination at six months of age.
Prof. Sucharit Bhakdi describes autoimmune disease as the result of immune cells incorrectly recognizing the body's own antigens.
Prof. Sucharit Bhakdi cites a summary of 87 cases of hepatitis after COVID-19 vaccination, 34 of which had no detected autoantibodies.
Prof. Sucharit Bhakdi points out that in the described case of hepatitis, a possible explanation was an immune attack against the spike protein, rather than autoimmunity.
Prof. Sucharit Bhakdi says that encephalitis diagnosed as autoimmune has been reported after mRNA vaccination, but its cause often cannot be determined without examining tissue.
Research from PubMed · Europe PMC
We selected 6 studies with the best, positive results. This is a selection, not a full review of all research.
Total number of studies on this topic in PubMed: 3 182.
A meta-analysis found no association between hepatitis B vaccination in adults and the occurrence of autoimmune diseases.
Aim of the study: To assess if hepatitis B vaccination in adults is causally associated with autoimmune diseases. Such causation has been claimed based mainly on case reports and uncontrolled studies, and a syndrome 'Autoimmune/autoinflammatory Disorder Induced by Adjuvants' (ASIA) has been claimed to be linked to immunization, particularly hepatitis B vaccination.
Results: Overall no association between hepatitis B vaccination and the onset of autoimmune diseases was seen. The overall odds ratio was 1.06, with 95% confidence limits of 0.93-1.21, with non-significant heterogeneity. Only one study showed a significant excess risk between hepatitis B immunisation and autoimmune disease. Despite multiple case reports, there is no reliable scientific evidence of autoimmune diseases being caused by hepatitis B vaccinations.
“Not stated” does not mean nobody paid — the database does not always record it.
A large study found no increased risk of Guillain-Barré syndrome after vaccination in adults.
Aim of the study: The role of vaccination in the development of Guillain-Barré syndrome (GBS) is controversial, although cases of GBS have been reported following a wide range of vaccines. A nested case-control study was conducted between January 2011 and December 2015 in three Chinese cities.
Results: Among paediatric and adult population, adjusted ORs for GBS occurrence within 180 days following vaccination were 0.94 (95% CI 0.54-1.62) and 1.09 (95% CI 0.88-1.32), respectively. No increased risk of GBS was detected for vaccination against hepatitis B, influenza, hepatitis A, varicella, rabies, polio(live), diphtheria, pertuss(acellular), tetanusis, measles, mumps, rubella, Japanese Encephalitis, and meningitis vaccines. Adjusted ORs for the recurrence of GBS after vaccination among paediatric and adult population were 0.85 (95% CI 0.07-9.50) and 1.18 (95% CI 0.49-2.65), respectively. In this large retrospective study, we did not find evidence of an increased risk of GBS and its recurrence among either paediatric (≤ 18 years) or adult (> 18 years) individuals within the 180 days following vaccinations of any kind, including influenza vaccination.
“Not stated” does not mean nobody paid — the database does not always record it.
The shingles vaccine was similarly effective in people with autoimmune diseases as in other people.
Aim of the study: Individuals with autoimmune or immune mediated diseases (AID) are more susceptible to infections and often experience worse outcomes if infected, underscoring the importance of vaccination. However, it remains unclear whether vaccine effectiveness (VE) differs between persons with and without AID.
Results: For the herpes zoster trial, 169,054 vaccinated individuals were matched to the same number of controls, including 10,994 AID individuals per group. Herpes zoster VE was 68.73 (95% CI 55.75-77.91) in the AID group and 60.30 (55.59-64.52) in the non-AID group (VE ratio: 1.14, 95% CI 0.93-1.30). Across four influenza seasons (2015/2016-2018/2019) between 1403,342 and 1713,064 individuals were included, including between 56,662 and 78,320 AID individuals. Influenza VE varied by outcome, season, and assumptions, but VE ratios remained near one in most analyses (VE ratios: -0.92-3.77), with all CIs including one. There was no evidence that VE differs meaningfully between individuals with and without AID, conditional on the included confounders. Both vaccines were similarly effective across groups, suggesting that VE is not reduced in MS, IBD, or CIRD patients. Further research is necessary to validate these findings for other AID and infections.
“Not stated” does not mean nobody paid — the database does not always record it.
People with rheumatoid arthritis reported similar rates of adverse events and hospitalizations to healthy people.
Aim of the study: The COVID-19 vaccination in autoimmune diseases (COVAD) study aimed to assess short-term COVID-19 vaccination-related adverse events (AEs) in RA patients.
Results: Of the 9462 complete respondents, 14.2% (n = 1347) had been diagnosed with RA; they had a mean (s.d.) age of 50.7 (13.7) years, 74.2% were women and 49.3% were Caucasian. In total, 76.9% and 4.2% of patients with RA reported minor and major AEs, respectively. Patients with active and inactive RA had similar AE and hospitalization frequencies. Overall, AEs were reported more frequently by BNT162b2 and mRNA-1273 recipients and less frequently by BBV152 recipients compared with the rest. Major AE and hospitalization frequencies were similar across recipients of different vaccines. Patients receiving methotrexate and hydroxychloroquine reported fewer minor AEs than those patients not on them. Compared with HCs and patients with other AIRDs, patients with RA reported similar total AEs, overall minor AEs, and hospitalizations.
“Not stated” does not mean nobody paid — the database does not always record it.
In people with weakened immune systems, including those with autoimmune diseases treated with immunosuppressants, COVID-19 vaccination was associated with a lower risk of severe consequences of infection, and studies did not show a consistent increase in disease flares.
Aim of the study: Immunocompromised individuals face elevated risks of severe COVID-19, yet vaccination guidance for these populations continues to evolve.
Results: Most studies had short follow-up durations, likely reflecting higher-end estimates of vaccine effectiveness. Given moderate certainty of benefit and low certainty of harm, the panel strongly recommends the 2025-2026 COVID-19 vaccine for all immunocompromised individuals aged ≥6 months, with timing tailored to immunosuppressive therapy, clinical stability, and community transmission levels. Adjunct strategies-including vaccination of household contacts and early antiviral access-remain essential. Research priorities include defining immunologic correlates of protection, evaluating durability, optimizing vaccine timing, and improving real-world effectiveness and safety data.
“Not stated” does not mean nobody paid — the database does not always record it.
Guidelines recommend COVID-19, influenza, and RSV vaccination for people with weakened immune systems, including patients with autoimmune diseases who take immunosuppressive medicines.
Aim of the study: Respiratory viruses-including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19), respiratory syncytial virus (RSV), and influenza-pose significant risks to immunocompromised patients, who experience attenuated vaccine responses and higher morbidity.
Results: Research gaps remain in immunogenicity, durability, and clinical effectiveness, particularly for patients receiving B-cell-depleting therapies or early post-transplant. Priority areas include defining correlates of protection, optimizing vaccine schedules, evaluating high-dose or adjuvanted formulations, and improving real-world effectiveness and safety data. Equity and access strategies are essential to ensure uptake among vulnerable populations. These guidelines aim to support evidence-based decision-making and highlight the need for harmonized, multi-virus research to inform tailored vaccination strategies for immunocompromised individuals.
“Not stated” does not mean nobody paid — the database does not always record it.
Perspectives and opinion materials
The content below presents the authors’ opinions, interpretations and hypotheses. It is not treated as equal to scientific studies and systematic reviews.
Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.